Menu
← Oncology Approval Tracker
FDA DECISION ·
Tibsovo
ivosidenib · Servier Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation confirmed by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The decision extends IDH1 inhibition from hematologic disease to an anatomically and molecularly defined biliary cancer population.
What research teams should watch
Retain the molecular report and prior systemic treatment and coordinate electrocardiogram monitoring.
PRIMARY RECORDS